I began my Ph.D. convinced I was on the brink of a billion-dollar idea — within my first semester, I was working on a device to detect biomarkers for prostate cancer. Humor me: I envisioned creating a “pee-stick,” like a pregnancy test but for men, and planned an early retirement on a farm in Oregon. But reality hit: I couldn’t patent it, couldn’t raise funding, and couldn’t bring it to life. That experience opened my eyes to a painful truth- there is a huge gap between science and the business of science.

Since then, my career has been defined by a singular mission: to bridge science, strategy, and entrepreneurship.

I became driven by a deeper goal — to improve biology, bedside and beyond. I didn’t just want to understand disease; I wanted to help translate science into solutions that could reach patients, markets, and society at large. Though formally trained with a Ph.D. in chemistry and a master’s in pharmacology, I left the bench — after roles at BASF and Celgene — to focus on the translational side of innovation.

As a tech transfer fellow at UCI, I saw early-stage discoveries begin to take shape as potential products. And by building my own nonprofit (a story for another day!), I learned firsthand what it means to lead something from zero. Each experience gave me a new lens on how science can move from lab to life.

That path led me to the Blavatnik Fellowship at Yale, where I had the opportunity to help scale academic science into venture-backed startups. Alongside this, I launched the aHs podcast to spotlight unfiltered conversations with healthcare builders and thinkers.

I co-founded Domillin, a company built on Yale technology, and led its development from concept to acquisition — leading fundraising efforts, and managing business development. Ultimately, we negotiated the sale of our assets to a buyer in Brazil. The experience gave me a firsthand view of what it takes to translate early-stage science into tangible value — navigating uncertainty, building alignment, and executing under pressure.

With a beautifully failed startup behind me and two demanding cats at home, I started as an investor at Flagship Pioneering. Here I work on company creation, diligence, and scaling ventures agnostic of therapeutic areas. The role has deepened my understanding of platform strategy and sharpened my instinct for scientific storytelling — learning not just how to evaluate bold ideas, but how to shape them into fundable, scalable companies.

I’ve also continued investing as an angel, sit on advisory boards, and stay close to the science by reviewing high-impact publications and supporting founders at the earliest stages.

At every step, I’ve sought to bridge the gap between breakthrough science and real-world impact. Whether investing, advising, or building, I remain driven by the belief that bold ideas deserve thoughtful execution and that science, when supported by the right capital and conviction, can change everything.

My work continues — at the edge of science, strategy, and storytelling. In the future, I aim to back the kind of science that doesn’t just push boundaries — it redefines what’s possible.